Drugs

Postmarket Drug and Biologic Safety Evaluations Completed from January 2017 – March 2017

 

Product Name: Trade (active ingredient)
with Dosage form NDA/BLA Number ("NME" indicates New Molecular Entity)  Approval Date
Major IndicationsSummary of Findings from EvaluationActions taken and Ongoing Surveillance Activities

Cosentyx
(secukinumab)
injection, for subcutaneous use
 

BLA 125504 (NME)
 

January 21, 2015

For treating adults with:

  • Plaque psoriasis
  • Psoriatic arthritis
  • Ankylosing spondylitis

Five potential safety issues were identified from postmarketing adverse event reports:

  • Sepsis and infection-related deaths
  • Neutropenia-related serious infection
  • Eczema
  • Lichen planus/lichenoid mucositis
  • Medication errors and device-related events

FDA is evaluating adverse event reports of sepsis and infection-related deaths, neutropenia-related serious infection, eczema, lichen planus/lichenoid mucositis, medication errors, and device-related events to determine if regulatory action is required.

Cuvposa
(glycopyrrolate)
oral solution
 

NDA 022571
 

July 28, 2010

For reducing chronic, severe drooling in patients who are 3 to 16 years of age with neurologic conditions associated with problem drooling

No new safety issues were identified.

No regulatory actions required at this time.

Cysview Kit
(hexaminolevulinate hydrochloride)
intravesical solution for bladder instillation only
 

NDA 022555
 

May 28, 2010

For cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy

No new safety issues were identified.

No regulatory actions required at this time.

Dysport
(abobotulinumtoxinA)
injection, for intramuscular use
 

BLA 125274 (NME)
 

April 29, 2009

For treating:

  • Cervical dystonia in adults
  • Upper limb spasticity in adults
  • Lower limb spasticity in pediatric patients 2 years of age and older
  • For cosmetic use to temporarily improve the appearance of moderate to severe glabellar lines

Two potential safety issues were identified from postmarketing adverse event reports:

  • Anaphylaxis
  • Dry eyes

FDA is evaluating adverse event reports of dry eyes to determine if regulatory action is required.
On June 14, 2017, a labeling supplement was approved that included the addition of information in the “Adverse Reactions; Postmarketing Experience” section of labeling pertaining to reports of hypersensitivity reactions, including anaphylaxis.

Edurant
(rilpivirine)
tablets, for oral use
 

NDA 202022 (NME)
 

May 20, 2011

For treating human immunodeficiency virus type 1 (HIV-1) infection, in combination with other antiretroviral agents, in treatment-naïve patients with HIV-1 ribonucleic acid or RNA less than or equal to 100,000 copies/milliliter

No new safety issues were identified.

No regulatory actions required at this time.

Epaned Kit
(enalapril maleate)
oral solution
 

NDA 204308
 

August 13, 2013

For treating:

  • Hypertension in adults and children older than one month
  • Symptomatic heart failure
  • Asymptomatic left ventricular dysfunction

No new safety issues were identified.

No regulatory actions required at this time.

Esomeprazole strontium
delayed-release
capsules, for oral use
 

NDA 202342
 

August 6, 2013

  • For treating gastroesophageal reflux disease in adults
  • For reducing risk of nonsteroidal anti-inflammatory drug-associated gastric ulcer in adults
  • For eradicating H. pylori to reduce the risk of duodenal ulcer recurrence in adults
  • For treating pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults

 

No new safety issues were identified.

No regulatory actions required at this time.

Glyxambi
(empagliflozin and linagliptin)
tablets, for oral use
 

NDA 206073
 

January 30, 2015

For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate

No new safety issues were identified.

No regulatory actions required at this time.

MenHibrix             (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine)
 

BLA 125363
 

June 14, 2012

Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b

No new safety issues were identified.

No regulatory actions required at this time.

Meropenem for Injection USP and Sodium Chloride Injection USP in Duplex container, for intravenous use
 

NDA 202106
 

April 30, 2015

For treating:

  • Complicated skin and skin structure infections
  • Complicated intra-abdominal infections
  • Bacterial meningitis

No new safety issues were identified.

No regulatory actions required at this time.

Neostigmine methylsulfate 
injection, for intravenous use
 

NDA 203629
 

January 8, 2015

For the reversal of the effects of nondepolarizing neuromuscular blocking agents after surgery

No new safety issues were identified.

No regulatory actions required at this time.

Pazeo
(olopatadine hydrochloride ophthalmic solution) 0.7%, for topical ophthalmic administration
 

NDA 206276
 

January 30, 2015

For treating ocular itching associated with allergic conjunctivitis

No new safety issues were identified.

No regulatory actions required at this time.

Perjeta
(pertuzumab)
injection, for intravenous use
 

BLA 125409 (NME)
 

June 8, 2012

  • For use in combination with trastuzumab and docetaxel for treating patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
  • For use in combination with trastuzumab and docetaxel as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 centimeters or node positive) as part of a complete treatment regimen for early breast cancer. 

Two potential safety issues were identified from postmarketing adverse event reports:

  • Angioedema
  • Tumor lysis syndrome

FDA continues to evaluate adverse event reports of angioedema and tumor lysis syndrome to determine if regulatory action is required.

Phenylephrine hydrochloride ophthalmic solution, USP 2.5% and 10%
 

NDA 207926
 

January 15, 2015

For dilating the pupil

No new safety issues were identified.

No regulatory actions required at this time.

Pomalyst
(pomalidomide) capsules, for oral use
 

NDA 204026 (NME)
 

February 8, 2013

For use in combination with dexamethasone to treat patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy

Three potential safety issues were identified from postmarketing adverse event reports:

  • Ischemic colitis
  • Pancreatitis
  • Progressive multifocal leukoencephalopathy

FDA is evaluating adverse event reports of ischemic colitis, pancreatitis, and progressive multifocal leukoencephalopathy to determine if regulatory action is required.

Potassium chloride
oral solution
 

NDA 206814
 

December 22, 2014

For the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient

No new safety issues were identified.

No regulatory actions required at this time.

Savaysa
(edoxaban)
tablets, for oral use
 

NDA 206316 (NME)
 

January 8, 2015

  • For reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

 

  • For treating deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial therapy with a parenteral anticoagulant therapy

No new safety issues were identified.

No regulatory actions required at this time.

Saxenda
(liraglutide)
injection, for subcutaneous use
 

NDA 206321
 

December 23, 2014

For use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia)

No new safety issues were identified.

No regulatory actions required at this time.

Simponi Aria
(golimumab)
injection, for intravenous use
 

BLA 125433 (NME)
 

July 18, 2013

For treating adult patients with moderately to severely active rheumatoid arthritis in combination with methotrexate

No new safety issues were identified.

No regulatory actions required at this time.

Toujeo
(insulin glargine injection) U-300, for subcutaneous use
 

NDA 206538
 

February 25, 2015

A long-acting human insulin analog for improving glycemic control in adults with diabetes mellitus

No new safety issues were identified.

No regulatory actions required at this time.

Trumenba
(Meningococcal Group B Vaccine)
 

BLA 125549
 

October 29, 2014

For active immunization to prevent invasive disease caused by Neisseria meningitides serogroup B in individuals 10 through 25 years of age

No new safety issues were identified.

No regulatory actions required at this time.

Viekira Pak
(ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)
co-packaged for oral use
 

NDA 206619 (NME)
 

December 19, 2014

For treating adult patients with chronic hepatitis C virus genotype 1 infection

No new safety issues were identified.

No regulatory actions required at this time.

Xofigo
(radium Ra-223 dichloride)
injection, for intravenous use
 

NDA 203971 (NME)
 

May 15, 2013

For treating castration-resistant prostate cancer in patients with symptomatic bone metastases and no known visceral metastatic disease

No new safety issues were identified.

No regulatory actions required at this time.

Yervoy (ipilimumab)
injection, for intravenous use
 

BLA 125377 (NME)
 

March 25, 2011

  • For treating unresectable or metastatic melanoma
  • For use as an adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 millimeter who have undergone complete resection, including total lymphadenectomy

Six potential safety issues were identified from postmarketing adverse event reports:

  • Neutropenia and/or febrile neutropenia
  • Thrombocytopenia
  • Retinal detachment
  • Blindness
  • Rhabdomyolysis
  • Acute febrile neutrophilic dermatosis

FDA continues to evaluate adverse event reports to determine if regulatory action is required.

 

Page Last Updated: 10/06/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English